5-Fluoropyrimidines have antineoplastic (e.g. 5-fluorouracil and its prodrugs capecitabine and tegafur) or antifungal (flucytosine) effects.
Affected agents and indications with approvals in Germany:
- 5-Fluorouracil (5FU) (i.v. in oncology, topically in dermatology:see under 5-Fluorouracil
)- Capecitabine (Xeloda and generics) (oral; oncology
)- Tegafur (monopreparations and combination preparation Teysuno) (oral; oncology
)- Flucytosine (oral, injection; antifungal).